A major goal of the initiative is to reduce fragmentation of medical care for the growing numbers of patients who have diabetes, obesity, chronic kidney disease, or cardiovascular risk for cardiovascular-kidney-metabolic syndrome. The new holistic, patient-centered approach to addressing cardiovascular-kidney-metabolic syndrome involves cooperation among medical disciplines.
Advances in stroke, a novel antihypertensive, and new evidence that diabetes drugs may offer CVD benefits for those without diabetes are among the top developments in 2023, on the AHA's annual list.
The SELECT trial catapulted GLP-1 RAs into the forefront of CVD prevention, but cardiologists are making their own decisions about whether and how they might integrate these agents into practice.
The overhaul of the widely used cardiac-risk algorithm is an acknowledgment that, unlike sex or age, race identification in and of itself is not a biological risk factor.